on Theranexus (EPA:ALTHX)
THX Pharma appoints Julien Veys as Deputy General Manager
On January 7, 2026, THX Pharma, a company specializing in rare neurological diseases, announced the appointment of Julien Veys as Deputy Chief Executive Officer. This decision supports the company's new strategy focused on the international commercialization of drugs such as TX01 and Batten-1.
Mathieu Charvériat, CEO of THX Pharma, highlights Veys' expertise in strategic development as a valuable asset for the company. Veys expresses its satisfaction in contributing to the company's evolution towards the commercialization of innovative therapies.
Veys, a key member of the company since 2016, has been involved in crucial milestones such as Theranexus's IPO and strategic agreements. Previously, he played a significant role at Trophos, notably during its acquisition by Roche.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news